Eli Lilly and Company (NYSE:LLY) Stock Price Down 0.9% – Time to Sell?

Eli Lilly and Company (NYSE:LLY) shares traded down 0.9% during trading on Monday . The stock traded as low as $740.01 and last traded at $741.50. 1,007,385 shares changed hands during trading, a decline of 68% from the average session volume of 3,183,533 shares. The stock had previously closed at $748.01.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on LLY. Evercore ISI raised Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Truist Financial raised their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research report on Thursday, October 10th. Redburn Atlantic raised shares of Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Barclays cut their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a report on Thursday, October 31st. Finally, Guggenheim raised their price objective on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,007.94.

Eli Lilly and Company Stock Performance

The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The stock has a market capitalization of $716.73 billion, a PE ratio of 81.62, a PEG ratio of 2.83 and a beta of 0.43. The firm has a 50 day moving average price of $865.01 and a 200-day moving average price of $870.32.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. During the same period last year, the company earned $0.10 earnings per share. The firm’s revenue was up 20.4% on a year-over-year basis. Research analysts expect that Eli Lilly and Company will post 13.2 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 0.69%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is 56.22%.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the sale, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.13% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in LLY. Tidal Investments LLC lifted its stake in shares of Eli Lilly and Company by 20.5% in the third quarter. Tidal Investments LLC now owns 49,562 shares of the company’s stock worth $43,909,000 after buying an additional 8,424 shares in the last quarter. Optimist Retirement Group LLC raised its holdings in Eli Lilly and Company by 20.2% in the 3rd quarter. Optimist Retirement Group LLC now owns 3,164 shares of the company’s stock valued at $2,803,000 after acquiring an additional 531 shares during the last quarter. Blankinship & Foster LLC acquired a new position in shares of Eli Lilly and Company during the 3rd quarter worth approximately $78,003,000. Destination Wealth Management grew its position in shares of Eli Lilly and Company by 1,373.9% in the third quarter. Destination Wealth Management now owns 27,326 shares of the company’s stock valued at $24,209,000 after purchasing an additional 25,472 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB increased its holdings in shares of Eli Lilly and Company by 132.7% in the third quarter. Wilmington Savings Fund Society FSB now owns 40,055 shares of the company’s stock valued at $35,486,000 after purchasing an additional 22,840 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.